"10.1371_journal.ppat.1005035","plos pathogens","2015-07-10T00:00:00Z","Morgan S A Gilman; Syed M Moin; Vicente Mas; Man Chen; Nita K Patel; Kari Kramer; Qing Zhu; Stephanie C Kabeche; Azad Kumar; Concepción Palomo; Tim Beaumont; Ulrich Baxa; Nancy D Ulbrandt; José A Melero; Barney S Graham; Jason S McLellan","Department of Biochemistry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America; Centro Nacional de Microbiología and CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain; MedImmune Inc., Gaithersburg, Maryland, United States of America; AIMM Therapeutics, Academic Medical Center, Amsterdam, Netherlands; Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America","Conceived and designed the experiments: MSAG TB UB NDU JAM BSG JSM. Performed the experiments: MSAG SMM VM MC NKP KK QZ SCK AK CP UB. Analyzed the data: MSAG SMM VM MC NKP KK QZ SCK AK CP UB NDU JAM BSG JSM. Wrote the paper: MSAG JAM BSG JSM.","I have read the journal's policy and the authors of this manuscript have the following competing interests: MC, BSG and JSM are inventors on patent applications describing the use of prefusion-stabilized RSV F glycoproteins as vaccine antigens. TB is an inventor on an international patent application describing the technology used to isolate AM14. MedImmune Inc owns the rights to antibody AM14. JSM is a consultant for MedImmune Inc. This does not alter our adherence to all PLOS policies on sharing data and materials.","2015","07","Morgan S A Gilman","MSAG",16,TRUE,7,11,15,4,TRUE,TRUE,FALSE,0,NA,FALSE
